Primary small cell undifferentiated (neuroendocrine) carcinoma of the maxillary sinus.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod

Department of Oral Medical Surgical Sciences, Westmead Centre for Oral Health, Westmead, New South Wales, Australia.

Published: November 2004

Primary small cell undifferentiated (neuroendocrine) carcinomas of the paranasal sinuses are extremely uncommon neoplasms. This tumor was first reported in this site in 1965, and since then there have been only 61 documented cases in the literature. The median age at presentation is 53 years, with no gender predilection. There is no reported association of occurrence of this tumor with either tobacco use or form of occupation, and case outcome is usually poor. We report a case in a 25-year-old man, initially treated as an odontogenic infection and thus delaying institution of appropriate management. Further investigation identified a locally advanced neuroendocrine carcinoma of the left maxilla. Despite radiotherapy and chemotherapy, the patient exhibited rapid tumor dissemination and died.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tripleo.2004.04.003DOI Listing

Publication Analysis

Top Keywords

primary small
8
small cell
8
cell undifferentiated
8
undifferentiated neuroendocrine
8
neuroendocrine carcinoma
8
carcinoma maxillary
4
maxillary sinus
4
sinus primary
4
neuroendocrine carcinomas
4
carcinomas paranasal
4

Similar Publications

Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study.

BMC Gastroenterol

December 2024

Department of Gastroenterology and Hepatology, Linkou Branch, Chang Gung Memorial Hospital, 5, Fu-Hsin Street, Guei-Shan District, Taoyuan, 33305, Taiwan.

Background/aims: The increasing use of biologic therapies for moderate to severe inflammatory bowel disease (IBD) highlights the importance of optimal treatment sequencing, particularly after vedolizumab (VDZ) exposure. Studies comparing the effectiveness of ustekinumab (UST) and antitumor necrosis factor (anti-TNF) agents post-VDZ are limited.

Methods: This retrospective study analyzed VDZ-experienced IBD patients treated with UST or anti-TNF (adalimumab and infliximab) from May 2019 to January 2024.

View Article and Find Full Text PDF

Background/aim: The efficacy of preoperative chemoradiotherapy (CRT) in lower rectal cancer is determined by its effects on the primary tumor. However, the effects on the mesorectum have not been investigated. Furthermore, edema in the dissection planes is frequently observed after postoperative CRT.

View Article and Find Full Text PDF

Background/aim: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.

Patients And Methods: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021.

View Article and Find Full Text PDF

Aims: It is unclear if a supportive bandage, removable splint, or walking cast offers the best outcome following low-risk ankle fractures in children. The aim of this study was to evaluate the feasibility of a randomized controlled trial to compare these treatments.

Methods: Children aged five to 15 years with low-risk ankle fractures were recruited to this feasibility trial from 1 February 2020 to 30 March 2023.

View Article and Find Full Text PDF

Aims: The Exeter femoral stem has a cemented, polished taper-slip design, and an excellent track record. The current range includes short-length options for various offsets, but less is known about the performance of these stems. The aim of this study was to compare the survival of short-length stems with standard-length Exeter stems.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!